Murine RAW264.7 cells as cellular drug delivery carriers for tumor therapy: a good idea?
- 18 Downloads
Macrophage-mediated drug delivery system has emerged and gained wide interest as a novel strategy for cancer treatment. Among them, RAW264.7 cell was commonly used as the macrophage model for antitumor drug loading and delivery. However, this cell line was a macrophage-like cancerous cell with both immunogenicity and pro-tumorigenic properties, which may interfere with the positive response of the host immune system to developed tumor. Thus, the safety and efficacy of the RAW264.7 cell line as a drug carrier for cancer therapy remain questionable. Here, we constructed doxorubicin-loaded RAW264.7 cells and examined its antitumor efficacy in S180 tumor-bearing mice. The bio-distribution of RAW264.7 cells was determined by in vivo imaging technique, showing a high accumulation level of RAW264.7 cells in mice livers, spleens, and thymuses. A phenomenon of accelerated tumor growth was observed in mice treated with doxorubicin-loaded RAW264.7 cells. Thereafter, the effect of frequency, dose, and viability of injected RAW264.7 cells on S180 tumor growth was further investigated. The underlying mechanism was confirmed, attributing to the immune tolerance induced by excessive RAW264.7 cells. Our findings emphasized the latent limitation of RAW264.7 cells as drug carrier in current researches, and provided an experimental basis for the clinical safety of cell-mediated drug delivery system.
KeywordsCell-mediated drug delivery system RAW264.7 cell Immune tolerance Doxorubicin
We would like to thank Experimental Animal Center of Shenyang Pharmaceutical University for their careful care to animals.
This work was funded by the National Natural Science Foundation of China (nos. 81703456 and 81373334) and Science and technology Department of Liaoning Province (no. 201601140).
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflicts of interest.
All procedures performed in studies involving animal experiments were in accordance with the ethical standards of the Animal Ethics Committee of Shenyang Pharmaceutical University. This article does not contain any studies with human participants performed by any of the authors.
- 10.Brynskikh AM, Zhao Y, Mosley RL, Li S, Boska MD, Klyachko NL et al (2010) Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson’s Disease. Nanomedicine Nanotechnol Biol Med 5:379–396Google Scholar
- 27.Xiang Luo LH, Zheng H, Liu M, Liu X, Li C, Qiu Q, Zhao Z, Cheng X, Lai C, Yuqing S, Yihui D, Yanzhi S (2018) Neutrophil-mediated delivery of pixantrone-loaded liposomes decorated with poly(sialic acid)–octadecylamine conjugate for lung cancer treatment. Drug Deliv 25(1):1200–1212CrossRefGoogle Scholar